Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 14, 2025

EU weighs curbs on Chinese medical device makers in public bids

By Philip Blenkinsop

BRUSSELS (Reuters) -EU medical device suppliers are not given fair access to China's public tenders, the European Commission concluded on Tuesday, a finding that could lead to restrictions on Chinese suppliers in Europe.

The EU executive said it could exclude Chinese bidders from EU public procurement markets or attach a penalty score to their bids for five years to tackle what it described as discrimination.

The Commission launched its first ever investigation in April 2024 under its International Procurement Instrument, which aims to ensure reciprocity.

The Commission said it had since found "clear evidence" that China had measures and practices favouring Chinese devices for hospitals and conditions in tenders leading to abnormally low bids that profit-oriented companies could not offer.

Beijing criticised the investigation's launch at the time and the report is likely to increase tensions. China's commerce ministry said last week that EU investigations into Chinese firms, notably those that manufacture electric vehicles, constituted unfair trade.

Chinese President Xi Jinping told European Council President Antonio Costa in a phone call on Tuesday he hoped the European Union could become a "a trustworthy partner for cooperation".

The Commission said the European Union was committed to engaging with China to end the discrimination, but if no acceptable solution was found, it could adopt corrective measures.

"If it finds that such measures are in the EU interest, they could include a restriction on, or exclusion of, Chinese bidders of government contracts in the EU," the Commission said.  

The Commission has previously said discussions with China on medical devices had been "fruitless".

(Reporting by Philip Blenkinsop and Bart MeijerEditing by Christina Fincher)

Recommended for you

  • US bans imports from 37 more Chinese companies over Uyghur forced labor, including Huafu Fashion

  • LVMH says 'impossible' to control final sales point after report of champagne shipments to Russia

  • Czech Republic's need for Russian oil ended by pipeline upgrade